Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 63 citing Ceglia: Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes.... (0.13 sec) 

Update in type 1 diabetes

- endojournals.org
GS Eisenbarth - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc
Synthesis: There has been recent progress in defining the genetics, pathogenesis, and natural
history of the disease. In addition, there is a major effort to develop immunotherapies to prevent
the disorder and to cure the ...
Cited by 30 - Related articles - All 3 versions

Cross-sectional and prospective study of lung function in adults with type 2 …

- diabetesjournals.org
HC Yeh, NM Punjabi, NY Wang, JS Pankow, BB … - Diabetes Care, 2008 - Am Diabetes Assoc
RESULTS—At baseline, adults with diabetes had significantly lower predicted FVC (96 vs. 103%, P <
0.001) and predicted FEV 1 (92 vs. 96%, P < 0.001) than those without diabetes. These differences
remained significant after ...
Cited by 14 - Related articles - BL Direct - All 7 versions

[PDF] Inhaled insulin: extending the horizons of inhalation therapy


VP Guntur, R Dhand - Respiratory care, 2007 - rtjournalonline.com
Targeted glycemic control in patients with type 1 and type 2 diabetes is grossly inadequate, despite
data demonstrating reduced microvascular and macrovascular diabetic complications with inten- sive
treatment. A significant proportion ...
Cited by 11 - Related articles - View as HTML - BL Direct - All 5 versions

[PDF] Terapêutica clínica–Insulina inalada para a diabetes mellitus Clinical therapeutics …


GT McMahon, RA Arky - N Engl J Med, 2007 - scielo.oces.mctes.pt
Resumo A propósito de um doente com diabetes mellitus (DM) tipo 2, com controlo glicémico
insuficiente com agen- tes orais, é feita uma recomendação terapêutica baseada na discussão
clínica e no mecanismo de ...
Cited by 27 - Related articles - View as HTML - BL Direct - All 14 versions

Pulmonary function changes related to acute and chronic administration of inhaled …


M Hegewald, RO Crapo, RL Jensen - Diabetes Technology & …, 2007 - liebertonline.com
The need for frequent insulin injections to achieve optimal glycemic control remains a major barrier
to initiating and maintaining insulin therapy in diabetes. The inhaled route of insulin ad-
ministration offers many potential ...
Cited by 9 - Related articles - BL Direct - All 3 versions

Recent advances in insulin treatment of children


AK Steck, GJ Klingensmith, R Fiallo-Scharer - Pediatric Diabetes, 2007 - interscience.wiley.com
Abstract: Since the findings of the Diabetes Control and Complications Trial became public in 1993,
intensive insulin therapy has been recommended for all children. However, successful implementation
remains a challenge because of ...
Cited by 7 - Related articles - BL Direct - All 3 versions

Lung function changes related to diabetes mellitus

- utsouthwestern.edu [PDF] 
CCW Hsia, P Raskin - Diabetes Technology & Therapeutics, 2007 - liebertonline.com
Diabetic microangiopathy targets the lung as it does other organs. Even though respiratory
dysfunction in most patients with diabetes is subclinical and rarely the presenting complaint, there
are several reasons why pulmonary ...
Cited by 7 - Related articles - BL Direct - All 9 versions

Developing a pulmonary insulin delivery system for patients with diabetes


G Dailey - Clinical therapeutics, 2007 - Elsevier
Results: Eight clinical studies to date have reported that IDPI consistently improved glycemic
control, whether used in combination with longer-acting SC insulin regimens in patients with type 1
or type 2 DM or to supplement or ...
Cited by 6 - Related articles - All 3 versions

Why is Exubera being withdrawn?


CJ Bailey, AH Barnett - British Medical Journal, 2007 - bmj.com
On 18 October Pfizer announced that it would withdraw the first inhaled insulin, Exubera, from the
market, as sales were too low. In January 2006 Pfizer bought the worldwide rights to Exubera from
Sanofi-Aventis for $1.3bn (£0.6bn; ...
Cited by 6 - Related articles - BL Direct - All 2 versions

Inhaled insulin: gone with the wind?


C Mathieu, EAM Gale - Diabetologia, 2008 - Springer
Yesterday it was going to sweep the world; today it is gone. Exubera is no more: there was no money
in it. As for the patients who volunteered to test the new therapy, and those to whom it has offered
a new lease of life: tough luck. ...
Cited by 5 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google